Clinical Trials at Delaware Health Center-Grady Cancer Center
As of August 2026, 25 paid clinical trials are recruiting at Delaware Health Center-Grady Cancer Center, located at OhioHealth Grady Memorial Hospital and Emergency Department, 561 W Central Ave, Delaware, OH 43015, phone (740) 615-1000 in Delaware, Ohio. Active studies at this site cover conditions such as Anatomic Stage IV Breast Cancer AJCC v8, Stage IV Lung Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
25 clinical trials at Delaware Health Center-Grady Cancer Center
·Clear filters·Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Common conditions studied in Delaware
- Anatomic Stage IV Breast Cancer AJCC v8 (3 active studies)
- Stage IV Lung Cancer AJCC v8 (3 active studies)
- Anatomic Stage II Breast Cancer AJCC v8 (2 active studies)
- Anatomic Stage III Breast Cancer AJCC v8 (2 active studies)
- Malignant Female Reproductive System Neoplasm (2 active studies)
- Metastatic Malignant Neoplasm in the Brain (2 active studies)
Leading research sponsors in Delaware
- NRG Oncology
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
- SWOG Cancer Research Network
- ECOG-ACRIN Cancer Research Group
Frequently asked questions
How many paid clinical trials are currently recruiting in Delaware?
There are approximately 25 recruiting clinical trials in Delaware, Ohio listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Delaware pay participants?
Most recruiting trials in Delaware compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Delaware?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Delaware?
The most common conditions under active study in Delaware include Anatomic Stage IV Breast Cancer AJCC v8 (3), Stage IV Lung Cancer AJCC v8 (3), Anatomic Stage II Breast Cancer AJCC v8 (2), Anatomic Stage III Breast Cancer AJCC v8 (2), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Delaware?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Delaware on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Delaware?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Delaware?
Recruiting research sites in Delaware include Delaware Health Center-Grady Cancer Center, Grady Memorial Hospital, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Delaware right now?
The largest active categories in Delaware are Cancer & tumors (24). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Delaware Health Center-Grady Cancer Center?
Delaware Health Center-Grady Cancer Center is located at OhioHealth Grady Memorial Hospital and Emergency Department, 561 W Central Ave, Delaware, OH 43015. Use the Google Maps link in the intro above to get directions.
How do I contact Delaware Health Center-Grady Cancer Center?
You can reach Delaware Health Center-Grady Cancer Center by phone at (740) 615-1000. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.